Table 4. Studies reporting use of Pazopanib in uncommon/unclassified STS subtypes.

Author	No. of patients (n)	HPE subtype	ORR	PFS (months)	mOS (months)
Frezza et al [10]	18	Epithelioid sarcoma	0%	3	NR
Touati et al [8]	11	Epithelioid sarcoma	11.1%	3.8	10.8
Stacchiotti et al [37]	30	ASPS	24.2%	13.6	NR
Kim et al [16]	6	ASPS	16.7%	5.5	NR
Stacchiotti et al [38]	26	Extraskeletal myxoid chondrosarcoma	18%	2-year PFS – 40%	NR
Kollár et al [18]	52	Angiosarcoma, haemangioendothelioma Intimal sarcoma	20% 20% 100%	3 NR NR	9.9 NR NR
Martin-Broto et al [17]	31	Solitary fibrous tumour	58%	9.8	49.8
Our study	33	Haemangiopericytoma, pleomorphic RMS (adult type), MFS, spindle cell sarcoma, MPNST, ASPS, haemangioendothelioma, epethelioid sarcoma, clear cell sarcoma, UPS. Retroperitoneal sarcoma, angiosarcoma	27.2%	10.3	17.8

NR, Not reported; HPE, Histopathological examination; ORR, Objective response rate; PFS, Progression free survival; OS, Overall survival; ASPS, Alveolar soft part sarcoma; MPNST, Malignant peripheral nerve sheath tumour; UPS, Undifferentiated pleomorphic sarcoma; RMS, Rhabdomyosarcoma